Milestone Pharmaceuticals Inc. (MIST) operates as a commercial-stage biopharmaceutical company with a sharp focus on cardiovascular treatments. At its core is etripamil, a short-acting calcium channel blocker delivered as a nasal spray for rapid, patient-led use. This approach stands out because it targets acute rhythm issues that often send patients to emergency rooms, and I have been following how this could shift treatment patterns.
The company was incorporated in Québec, Canada, in 2003 and maintains its headquarters in Montreal along with operations in Charlotte, North Carolina. Resources are concentrated on research, development, and bringing cardiovascular products to market. I also checked this using Tickeron’s AI Screener to compare MIST against peers in the sector.
The flagship asset is CARDAMYST, the branded name for etripamil nasal spray. This formulation allows patients to self-administer treatment for sudden episodes of rapid heartbeat. CARDAMYST earned FDA approval in late 2025 specifically for converting acute symptomatic paroxysmal supraventricular tachycardia (PSVT) episodes to normal rhythm in adults.
Development continues for atrial fibrillation with rapid ventricular rate (AFib-RVR). A Phase 3 trial called ReVeRA-301 is underway, with topline results expected in the second half of 2028. Management views this indication as offering a much larger patient base than PSVT.
As an early-commercial biotech, Milestone generates revenue primarily from U.S. sales of CARDAMYST, supported by a licensing deal with Corxel Pharmaceuticals for territories including Greater China. Like many peers at this stage, the company has not produced operating profits and does not pay dividends, channeling funds instead into commercialization and further trials.
Competition comes from larger pharmaceutical players and established protocols in cardiovascular care. The nasal-spray format provides a clear point of difference by enabling on-demand use outside clinical settings.
Interest in MIST centers on upcoming clinical and commercial milestones rather than immediate earnings. The CARDAMYST rollout is the first real test of demand for a self-administered PSVT option, with metrics such as prescription trends, prescriber adoption, and insurance coverage serving as key signals. From what I see, the longer-term outlook hinges on success in AFib-RVR, which could expand the overall opportunity if the Phase 3 data are positive and lead to approval. Cash runway through these readouts remains a critical factor.
Investing in MIST involves the typical uncertainties of small-cap biotech. Early commercialization of CARDAMYST leaves questions around adoption speed, reimbursement, and uptake. Reliance on a single molecule creates concentration risk, and setbacks in clinical, regulatory, or commercial areas could have outsized effects. Additional challenges include competition in cardiovascular therapies, trial uncertainties, potential capital needs that may dilute shareholders, and broader regulatory or macroeconomic influences on the sector.
When evaluating names like MIST alongside other opportunities, I have found Tickeron’s AI Screener useful for quickly filtering biotech and broader market ideas based on technicals, fundamentals, volatility, and custom criteria. It helps narrow the field to matches for specific strategies without replacing deeper fundamental work.
Milestone Pharmaceuticals is working to introduce a patient-administered option for acute cardiac rhythm conditions. With CARDAMYST now approved and the AFib-RVR program moving through late-stage trials, commercial progress and clinical outcomes will shape its trajectory. For investors, MIST represents a focused, higher-risk profile within biotechnology that merits close monitoring of execution and data.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MIST may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 33 of 37 cases where MIST's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.
The RSI Indicator entered the oversold zone -- be on the watch for MIST's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +7.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where MIST advanced for three days, in 220 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MIST as a result. In 72 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for MIST turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 41 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MIST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for MIST entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.213) is normal, around the industry mean (3.498). P/E Ratio (-1.174) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (44.843) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. MIST’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MIST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer and manufacturer of cardiovascular medicines
Industry Biotechnology